Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (51-60 of 222) with videos related to

Pageof 23
Sort By:
Molecular Cancer Research : MCR|February 7, 2013
Role of WNT7B-induced noncanonical pathway in advanced prostate cancerDali Zheng, Keith F Decker, Tianhua Zhou, et al.
Cancers|December 7, 2017
Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and QuestionsOsama S Mohammad, Michael D Nyquist, Michael T Schweizer, et al.
Oncogene|June 23, 2020
Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancerEric A Nollet, Marina Cardo-Vila, Sourik S Ganguly, et al.
Neoplasia (New York, N.Y.)|October 13, 2006
Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genesIlsa M Coleman, Jeffrey A Kiefer, Lisha G Brown, et al.
Anticancer Research|July 3, 2017
Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279Brian Winters, Lisha Brown, Ilsa Coleman, et al.
ACS Chemical Biology|September 27, 2017
Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer DevelopmentJin-Hee Lee, Bing Yang, Anastasia J Lindahl, et al.
Cancer Research Communications|December 23, 2022
IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasisAnthony DiNatale, Asurayya Worrede, Waleed Iqbal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate CancerIlsa M Coleman, Navonil DeSarkar, Colm Morrissey, et al.
Bone|August 18, 2015
Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivoMarie-Therese Haider, Keith D Hunter, Simon P Robinson, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2025
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic targetXiong Zhang, Yatian Yang, Hongye Zou, et al.
Pageof 23

Showing results (51-60 of 222) with videos related to

Sort By:
Pageof 23
Molecular Cancer Research : MCR|February 7, 2013
Role of WNT7B-induced noncanonical pathway in advanced prostate cancerDali Zheng, Keith F Decker, Tianhua Zhou, et al.
Cancers|December 7, 2017
Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and QuestionsOsama S Mohammad, Michael D Nyquist, Michael T Schweizer, et al.
Oncogene|June 23, 2020
Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancerEric A Nollet, Marina Cardo-Vila, Sourik S Ganguly, et al.
Neoplasia (New York, N.Y.)|October 13, 2006
Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genesIlsa M Coleman, Jeffrey A Kiefer, Lisha G Brown, et al.
Anticancer Research|July 3, 2017
Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279Brian Winters, Lisha Brown, Ilsa Coleman, et al.
ACS Chemical Biology|September 27, 2017
Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer DevelopmentJin-Hee Lee, Bing Yang, Anastasia J Lindahl, et al.
Cancer Research Communications|December 23, 2022
IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasisAnthony DiNatale, Asurayya Worrede, Waleed Iqbal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate CancerIlsa M Coleman, Navonil DeSarkar, Colm Morrissey, et al.
Bone|August 18, 2015
Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivoMarie-Therese Haider, Keith D Hunter, Simon P Robinson, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2025
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic targetXiong Zhang, Yatian Yang, Hongye Zou, et al.
Pageof 23